【摘 要】
：
目的：探讨颈椎后凸畸形的手术治疗方法及其疗效.方法：本组共21例，男9例，女12例；年龄21-72岁，平均49岁；病因：炎症5例，颈椎病3例，后路全椎板切除术后2例，强直性脊柱炎2例，肿瘤或肿瘤样病变5例，陈旧性损伤4例.所有患者术前测量颈椎后凸角评价、评价颈椎柔韧度.根据不同病因、柔韧性、脊髓压迫情况等因素采用单纯前路、单纯后路或前后路联合手术，术后随访时间18-96个月，术后疗效评价包括颈椎后
论文部分内容阅读
目的：探讨颈椎后凸畸形的手术治疗方法及其疗效.方法：本组共21例，男9例，女12例；年龄21-72岁，平均49岁；病因：炎症5例，颈椎病3例，后路全椎板切除术后2例，强直性脊柱炎2例，肿瘤或肿瘤样病变5例，陈旧性损伤4例.所有患者术前测量颈椎后凸角评价、评价颈椎柔韧度.根据不同病因、柔韧性、脊髓压迫情况等因素采用单纯前路、单纯后路或前后路联合手术，术后随访时间18-96个月，术后疗效评价包括颈椎后凸角恢复及Odom分级标准.结果：单纯前路8例，单纯后路4例，前后路联合手术9例；其中前路平均融合3.6个节段，后路平均融合5.2个节段.术前后凸角平均29°，术后平均-10°，平均矫正角度39°；根据Odom标准：优8例，良10例，可2例，差1例.1例患者术后内固定失败、复法后凸畸形行翻修术，余患者术后均获骨性融合、后凸矫正随访期内无显著丢失.结论：颈椎后凸畸形的手术治疗应根据病因、柔韧性、脊髓压迫情况以及引起僵硬畸形的结构等来综合评价、制定个体化的治疗方案.对于柔韧性佳的患者，单纯前路或后路均可获满意效果；对于柔韧性差、僵硬畸形主要来自于后方小关节者，需前后路联合手术；对于柔韧性差、僵硬畸形非来源于后方小关节者，单纯前路也可获良好疗效.
其他文献
Modem production technologies and novel facility design philosophies have the potential to revolutionize the business case for MAb development and production facilities.Bringing MAb products from deve
This presentation looks at the design of a new facility dedicated to streamline production of MAb clinical supply in close proximity of our existing R & D center.From initial concept to construction,
A proof of concept study is presented demonstrating the potential of small molecule affinity ligands as a qualitative and economic alternative to Protein A for the purification of monoclonal antibodie
Periostin (PN), an extracellular matrix protein, is reported to be overexpressed in a variety of human cancers and its functions appear to be linked to tumor angiogenesis and metastasis.Our previous r
The identification of peptide epitopes with techniques such as phage display peptide libraries has opened the opportunity to develop specific targeting molecules for a variety of antibody-based biomed
The presentation will provide an overview of the U.S.Food and Drug Administration (FDA) approval process for follow-on biologics under the new U.S.healthcare law; the doctrine of Patent Misuse in the
Molecular Biology is a disruptive technology in the pharmaceutical industry, roiling the established order, creating new paradigms for drug discovery and development, and ultimately for medicine itsel
Approved and investigational therapeutic monoclonal antibodies (mAbs) represent the leading sector of the biopharmaceuticals market and research.However, pursuing mAb affinity and structural similarit
Antibodies have rapidly become a mainstay of therapeutics.The bispecific antibody (bsAb) field has evolved over the past two decades mainly for applications that cannot be easily achieved by monospeci
We have developed two novel antibody formats: Fcabs, in which antigen-binding sites are introduced into a human Fc fragment and mAb2s, in which additional binding sites are engineered into the Fc of a